Table 1
From: Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy
NELFINAVIR | LOPINAVIR/RITONAVIR | p | |
|---|---|---|---|
Age (yr) | 32 (28–36) | 32 (26–36) | NS |
C3 category | 21 (10) | 21 (19) | 0,026 |
CD4 (cells/μL) at 1st visit | 477 (325–652) | 426 (264–600) | NS |
Viral load < 50 copies/ml at 3rd trimester | 142 (70) | 61 (62) | NS |
Hepatitis C | 79 (35) | 40 (33) | NS |
HAART-naive patients | 108 (48) | 35 (29) | 0.001 |
Gestational diabetes mellitus | 15 (8) | 5 (5) | NS |
Vomiting | 9 (4) | 16 (14) | <0.001 |
Diarrhoea | 27 (12) | 15 (14) | NS |
Discontinuation of LPV or NFV. | 23 (10) | 12 (10) | NS |
Discontinuation of LPV or NFV due to virologic failure. | 1 (0.4) | 1 (0.8) | NS |
Vertical transmission | 1 (0.4) | 0 | NS |